nouscom, Autore presso Nouscom

Nouscom is presenting at the virtual Spring Private Company Showcase 2021 on March 11th

Find out more about the program and register here: Spring Private Company Showcase « Solebury Trout Access

Nouscom is presenting at the Biocapital Europe 2021 on March 11th

Find out more about the program and register here: https://www.biocapitaleurope.com/programme/

Nouscom appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer

BASEL, Switzerland – 11th December 2020: Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized genetic cancer vaccines, today announces that it has appointed [...]

Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment

Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an [...]

New viral vectors for infectious diseases and cancer

ABSTRACT – Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and finally eradicate smallpox, the concept of using a virus to fight another virus has evolved [...]

Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability

22th July 2020 – Article entitled ‘A genetic vaccine encoding shared cancer neoantigens to treat tumors with Microsatellite Instability’ published in Cancer Research Nouscom, an [...]

Nouscom Strengthens its Management Team

26th February 2020 – Marina Udier, PhD, appointed as Chief Executive Officer and Patricia Delaite, MD, appointed as Chief Medical Officer Nouscom, an immuno-oncology company developing [...]

Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors

BASEL, Switzerland – 9 December 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has been [...]

Nouscom will join & present at the SITC 2019

Nouscom will join & present at the SITC 2019 from November 6-10.

Nouscom will present at the 2nd European Oncology and Immono-Oncology Drug Discovery Symposium

Nouscom will present at the 2nd European Oncology and Immono-Oncology Drug Discovery Symposium on October 22, 2019 in Basel.